Answers are grounded in this paper and cite their sources.
Serum cystatin C has been well established as an early and accurate biomarker of CKD that is particularly helpful in patients for whom creatinine is an inadequate marker or for whom more cumbersome methods of glomerular filtration rate (GFR) measurement are impractical. Current research questions are no longer focused on if, but rather when and how often cystatin C should be used in the evaluation of CKD patients. However, transition of all reagents and estimated GFR equations to the newly established International Standard is critical for developing generalizable data.
No takes yet. Share an insight, caveat, or question.
Benoit et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: